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Purpose: To evaluate the structure-modifying and symptom efﬁcacy, as well as safety and tolerability of
oral salmon calcitonin (sCT) formulated with a 5-CNAC carrier (a molecule based on Eligen® technology),
in osteoarthritis (OA) patients with moderate to severe knee pain and joint structural damage classiﬁed
as Kellgren and Lawrence (KL)2e3.
Methods and design: This is the combined reporting of two randomized, double-blind, multi-center,
placebo-controlled trials (CSMC021C2301 and CSMC021C2302), evaluating the efﬁcacy and safety of oral
sCT in patients with painful knee OA with structural manifestations, enrolling 1176 and 1030 patients,
respectively. Study subjects were randomized (1:1) to oral sCT 0.8 mg twice daily or placebo (PBO) for 24
months. The primary efﬁcacy objectives were to examine the treatment effect compared to placebo on
change over 24 months in joint space width (JSW) in the signal knee measured by X-ray, and to examine
the change in pain and function using the Western Ontario and McMaster Universities Osteoarthritis
(WOMAC) questionnaire. Other study parameters included patient and physician global assessment, and
biochemical markers of bone (CTX-I) and cartilage degradation (CTX-II).
Results: At the 24 month endpoint there was no statistically signiﬁcant treatment effect on joint space
narrowing (JSN) in any of the two studies. In CSMC021C2301 there was a treatment effect on WOMAC
(sum of pain, function, stiffness, and total scores) as well as on the biomarkers of bone and joint
metabolism, but due to the hierarchical testing procedure the treatment effect was not claimed statis-
tically signiﬁcant.
Conclusions: The present formulation of oral sCT did not provide reproducible clinical beneﬁts in patients
with symptomatic knee OA (NCT00486434, NCT00704847).
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most common form of arthritis1,2 with
20 million individual affected in the US alone. OA is a painful,
disabling disease affecting the synovial joints resulting in stronglyspace width; JSN, Joint space
eptide of type I collagen; OC,
collagen; WOMAC, Western
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ternational. Published by Elsevier Lreduced quality of life. Currently there is no structure modifying
treatments approved for OA. The exact etiology of OA is still rela-
tively unknown, but risk factors such as age3, obesity3e6, genetic
predisposition3,7, joint mal-alignment8, acute joint injury3,9 and
reduced sex hormone levels in relation to menopause2 are known
to be involved. There is an urgent medical need for development of
a structure modifying treatment for OA. Several different ap-
proaches have been undertaken including bisphosphonates, INos
inhibitors which until know all have failed pivotal phase III studies,
albeit strontium ranelate did demonstrate positive effect on some
parameters. As OA is a becoming recognized as a multi-factorial
disease of the whole joint involving the bone, cartilage and syno-
vium compartments, one singlemagic bullet for this diverse patient
population may be a futile task.td. All rights reserved.
M.A. Karsdal et al. / Osteoarthritis and Cartilage 23 (2015) 532e543 533Calcitonin, a 32-amino-acid peptide, has demonstrated protec-
tive activity on both bone and cartilage in many different OA
models as well as preliminary clinical settings10e19. Available as an
injection or nasal spray since the 1970s to treat osteoporosis,
calcitonin inhibits bone resorption by binding and activating to the
calcitonin receptor on osteoclasts20,21. Salmon calcitonin (sCT)
formulated in a tablet with the carrier 5-CNAC,8-(N-2-hydroxy-5-
chloro-benzoyl)-amino-caprylic acid)22, an uni-molecular
enhancer of gastrointestinal peptide absorption is the ﬁrst protein
developed for oral administration and assessed in a phase III clinical
trial. Several Phase I studies have been performed to obtain a
suitable oral formulation with optimal dosing parameters. These
investigations have included (1) time of day for dosing (morning or
evening)23, (2) food intake24, (3) water intake16,25, (4) synthetic vs
recombinant productions26 of the peptide and was recently
reviewed and published27.
In the present study, we assessed the efﬁcacy and safety of oral
sCT in symptomatic OA in two phase III clinical studies.
Materials and methods
Study description
The two studies (CSMC021C2301, NCT00486434) and
(CSMC021C2302, NCT00704847) were double blinded, random-
ized, placebo-controlled andmulti-center phase III clinical trials for
the assessment of an oral formulation of 0.8 mg sCT (Novartis
Pharma AG) twice daily or matching placebo for 24 month, 19 sites
in 11 countries. Patients aged 51e80 years with painful OA of at
least one knee, but who were otherwise in good general health
were recruited into two independent international double-blind
Phase III trial. Patients were not to consume food for 1 h before
receiving study medication. After taking each tablet with a
maximum of 50 ml of water, patients were to wait at least 30 min,
without further liquid, before consuming breakfast or dinner.
To be included, patients had to meet the American College of
Rheumatology (ACR) criteria for diagnosis of OA. Both knees were
assessed during the study, but a signal knee was identiﬁed prior to
randomization for assessment of the primary efﬁcacy endpoint. The
signal knee had to be painful on most days of the prior month. In
addition the patient had to fulﬁll at least one of the following
criteria: age over 50 years, experience morning stiffness lasting less
than 30 min, or knee crepitus. The signal knee had to have a joint
space width (JSW) 2.0 mm at the medial tibio-femoral joint as
measured on X-ray, and have a Kellgren and Lawrence (KL) score of
2 (deﬁnite osteophyte and possibly joint space narrowing (JSN)) or
3 (multiple osteophytes, deﬁnite JSN, some sclerosis, and possible
deformity of the bone contour). On Western Ontario and McMaster
Universities Osteoarthritis (WOMAC) subscales, patients were to
score150mm for pain and/or510mm for function. If both knees
fulﬁlled the criteria, the signal knee was deﬁned as the knee that
meets KL score of 2. If both knees had KL scores of 2 the knee with
the highest pain VAS was selected (as long as it was below 80 mm).
Exclusion criteria included diseases (apart from OA) and medi-
cations that affected bone or cartilage metabolism. Pain relief
medicationwas allowed, provided it was taken at least 30 min after
the study drug. Intra-articular injection of corticosteroids or hyal-
uronic acid in the signal kneewas prohibited during the study and 3
months prior to randomization.
Randomization was stratiﬁed by center and it was ensured that
treatment assignment was unbiased and concealed from patients
and investigator staff. At study entry a patient was allocated the
lowest available number on the randomization list available for the
given site. The randomization list was produced by Novartis Drug
Supply Management using a validated system that automated therandom assignment of treatment arms to randomization numbers
in the speciﬁed ratio. The randomization numbers were linked to
medication numbers. The SMC021 tablets were supplied to the
investigators at a dose strength of 0.8 mg packaged in a blinded
fashion. Matching placebo tablets were supplied in identical
packaging.
The trial was conducted in accordance with the Declaration of
Helsinki. The protocol was approved by independent ethics com-
mittees or institutional review boards (IEC/IRB). All subjects or legal
representatives gave their informed consent to take part. The
enrollment date was deﬁned as the date the subject signed the
Informed Consent.
X-RAY of the knee
X-rays images of both knees were obtained to assess the KL
grading and JSW. A signal knee was identiﬁed prior to randomi-
zation for the assessment of the primary efﬁcacy endpoints. The
protocol was not ﬂuoroscopically assisted. It was mandatory to use
the Syna-Flex™ device, to make sure that the positioning was
consistent. The subject was positioned in the equipment in aweight
bearing position, ﬂexing the knees until having the thighs in touch
with Syna-Flex™, while the toes were touching the equipment. In
order to ensure a similar degree of positioning in all subjects, there
was a ﬁxed external rotation of both feet determined by the Syna-
Flex™ equipment.
Pain and function assessments
The subjects were instructed to read each question carefully and
mark an X on the line that best represented their answer. The study
staff only answered technical questions that did not bias the sub-
ject's ratings. Pain, stiffness and function were assessed by the
Western Ontario and McMaster Universities Arthritis (WOMAC)
version VA3.128 questionnaire and 24 h patient reported pain (vi-
sual analogue scales (VAS) pain) as well as patient/physician's
global assessment of disease activity, were assessed by VAS on a
100 mm VAS by placing an X on the line that best described the
pain, where 0 equaled to “No Pain” and 100 equaled to “Worst Pain
Imaginable, or “Very Good” to “Very Poor. The WOMAC scale is
designed to assess pain, stiffness and physical function in patients
with knee OA. The three domains (i.e., pain, stiffness and physical
function) are represented by 5, 2 and 17 questions, respectively. The
version used in these studies were the 100 mm VAS giving each
question a score from 0 to 100. The range for the pain domain is
0e500, the range for stiffness is 0e200 and the range for function is
0e1700.
The subjects were informed not to take any analgesics for 3 days
prior to this test prior to all visits where these questionnaires were
completed. Outside 3 days prior to a visit with questionnaires the
patients were allowed concomitant analgesic usage of NSAIDs,
Paracetamol and combinations thereof with low-dose codeine. This
was recorded by the subjects on diaries that were transferred to the
Electronic Care Report Forms.
Blood and urine sampling
Blood and urine samples for serum measurement of bone and
cartilage biomarkers were taken at baseline and every 6 months
and sent to a central laboratory for assessment. Plasma samples
were forwarded to Novartis for assessing levels of sCT and calci-
tonin antibody (at 0 and 24 months). All blood samples were ob-
tained after overnight fasting and by vein puncture before study
drug administration. Second morning void urine samples were to
be collected at the clinic.
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Sample size estimation
Each of the studies was powered to demonstrate signiﬁcance at
the 5% level of signiﬁcance (two-sided test) in the co-primary
endpoints. For the JSN it was assumed a 0.17 mm decrease in JSW
per year in the placebo group, a 40% protection of progression in the
treatment group, and a common standard deviation after 2 years of
0.5mm. For theWOMAC pain score an improvement of 8mm at the
2-year endpoint was assumed for the placebo group, improvement
of 40mm in the treatment group, and a common standard deviation
of 120 mm. For the WOMAC function score an improvement of
60 mm at the 2-year endpoint was assumed for the placebo group,
improvement of 160 mm in the treatment group, and a common
standard deviation of 400 mm. Given the assumptions above and
assuming a dropout rate of 30% the CSMC021C2301was powered by
97% on JSW, 96% on WOMAC pain, and 94% on WOMAC by enroll-
ment of 575 subjects per treatment group, and CSMC021C2302 was
powered by 93% on JSW and 92% by enrollment of 460 subjects per
treatment group.Fig. 1. CONSORTBaseline characteristics
Student's t test and Fishers exact test were used to compare
baseline characteristics in demographic or other characteristics
between the two studies.
Efﬁcacy parameters
The primary analytical approach for CSMC021C2301 was to use
inferential testing to demonstrate the beneﬁt of oral sCT to main-
tain JSW and to reduce pain and functional disability measured by
the WOMAC scores compared to placebo. A hierarchical testing
procedure was implemented (1. JSW, 2. WOMAC pain, 3. WOMAC
function) on a two-sided signiﬁcance level of 5%. The two-sided
P-values had to be in favor of sCT in order for the conﬁrmatory
testing procedure to continue. CSMC021C2302 included two co-
primary endpoints of JSW and WOMAC pain tested in the same
hierarchical order (1. JSW, 2. WOMAC pain). The statistical signiﬁ-
cance of the treatment effect was calculated from a mixed model
with repeated measures and unstructured covariance matrix with
baseline value as a covariate and body mass index (BMI) level at
baseline, treatment, visit, baseline by visit interaction, BMI by visitdiagrams.
Fig. 1. (continued).
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ANCOVA model). The effect size estimates of treatment difference
(Active treatment - Placebo) incl 95% CIs were from the MMRM
ANCOVA model. The MMRM ANCOVA model was the pre-speciﬁed
primary analysis method with no imputation of missing data. The
analysis of data of the combined studies was a post-hoc analysis not
deﬁned a priori and the combined data was analyzed in a MMRM
ANCOVA model similar to the model of the individual studies.
In the MMRM ANCOVA model the data of the biomarkers rela-
tive to baseline were logarithmically transformed to obtain sym-
metry of variance.
All statistical analyses were performed using SAS© software,
version 9.3.
Safety parameters
Analysis of Adverse Events (AEs) were focused on treatment
emergent AEs in the safety population. The number and percentage
of patients were summarized by treatment according to theprimary system organ class and preferred term. Patients experi-
encing a speciﬁc AE more than once were categorized with the
most severe AE reported.
Evaluation of laboratory determinations were focused on
changes from baseline and presented in clinical shift tables (i.e.,
cross tabulations of low, normal, and high values from baseline to
each treatment visit). Additionally frequency tables of clinical
notable abnormal values were prepared.
Results
Consort description
The present study includes the analysis of two independent
phase III clinical trials, CSMC021C2301 and CSMC021C2302,
screening 1680 and 1568 subjects, respectively, where a total of
1176 and 1030 were randomized 1:1 to the two treatment arms
[Fig. 1(A) and (B)]. The main cause of exclusion was failure to meet
the inclusion criteria including a KL of the knee of more or less than
M.A. Karsdal et al. / Osteoarthritis and Cartilage 23 (2015) 532e5435362 or 3. The number of completed were 394 and 300 in the treat-
ment and 454 and 339 in the placebo group [Fig. 1(A) and (B)].
Study demographics and baseline patient description
The demographics of the intent-to-treat (ITT) population, which
consisted of all patients randomized and received at least one dose
of the study medication, are given in Table I, and the biomarker
baseline values are given in Table II. Within each study the popu-
lation was well balanced. Comparison of the two studies revealed
statistically signiﬁcant higher number of males in CSMC021C2302
(P ¼ 0.0002), higher number of Asians (P < 0.0001), slightly higher
JSW of target knee (P ¼ 0.02), higher number of patients with KL
grade 3 (P < 0.0001), more WOMAC pain (P ¼ 0.002), and slightly
higher levels of the biomarkers (serum CTXI: P ¼ 0.003; serum OC:
P ¼ 0.0001; urine CTXI: P ¼ 0.03; urine CTXII: P ¼ 0.0004).
Endpoint measures
JSW was measured at baseline, 12 and 24 months. There was no
signiﬁcant treatment effect in either study of change in JSW at the
24 month study endpoint (target knee: P ¼ 0.96; P ¼ 0.25; non-
target knee: P ¼ 0.37; 0.39) (Fig. 2). The WOMAC questionnaire
was completed at baseline, 3, 6, 12 and 24 months. Across the visits
the WOMAC scores decreased in both studies irrespective of
treatment. At the 24 month endpoint a treatment effect was
observed in CSMC021C2301 with a larger decrease in WOMAC pain
and function in signal knee in the treatment group than in the
placebo group (P ¼ 0.002, P ¼ 0.008). The treatment effect is
considered non-signiﬁcant due to the hierarchical testingTable I
Demographic characteristics in ITT population [n (%) and mean (SD)]
2301 2301 230
sCT Placebo sCT
N ¼ 585 N ¼ 584 N ¼
Sex e n (%)
Male 169 (28.9) 201 (34.4) 19
Female 416 (71.1) 383 (65.6) 32
Age (years) 64.6 (6.83) 64.4 (6.42) 64
Race e n (%)
White 532 (90.9) 532 (91.1) 44
Asian 53 (9.1) 51 (8.7) 7
Other - (-) 1 (0.1)
BMI (kg/m2) 29.1 (4.87) 28.8 (4.48) 29
JSW (mm)* 3.35 (0.92) 3.39 (1.00) 3.4
KL index n (%)*
Grade 2 513 (87.7) 513 (87.8) 40
Grade 3 72 (12.3) 71 (12.2) 11
WOMAC pain (mm)* 237 (77) 238 (75) 24
WOMAC total (mm)* 1133 (373) 1137 (383) 112
* Target knee.
Table II
Biomarker values at baseline in biomarker population (geometric mean and geometric ±
2301 2301 2302
sCT Placebo sCT
N ¼ 578 N ¼ 577 N ¼ 69
Baseline serum CTXI (mg/ml) 0.220 (0.134e0.362) 0.216 (0.135e0.346) 0.237 (0
Baseline serum OC (mg/ml) 22.6 (16.1e31.6) 22.4 (16.0e31.4) 20.0 (1
Baseline urine CTXI
(mg/mmol creatinine)
1.53 (0.84e2.77) 1.49 (0.84e2.65) 1.61 (0
Baseline urine CTXII
(ng/mmol creatinine)
236 (130e427) 223 (124e402) 264 (1procedure. No treatment effect was observed in CSMC021C2302, in
either WOMAC pain (P ¼ 0.68) or WOMAC function (P ¼ 0.97)
(Fig. 3). The effect estimates of treatment difference at the various
time points (Active treatment e Placebo) incl 95% CIs are given in
Table IV.
Biomarkers
There was a 15e20% reduction in the bone resorption marker of
urinary CTX-I in the sCT-treated group in the CSMC021C2301 study
throughout the study period (Fig. 4, Table IV). Likewise initially
there was a 20% reduction in CTX-I in the sCT-treated group in
CSMC021C2302, which however declined to 8% at the 24 months
study endpoint. There was a 12% reduction in bone formation
marker of serum osteocalcin in the sCT-treated group in
CSMC021C2301 throughout the study. In alignment with the bone
resorption data, a similar decrease of 12% was found at month 12 in
the sCT-treated group in CSMC021C2302, but this decreasewas non
persistent and at study end only a 2% decrease was observed. There
was a 10% treatment decrease in the cartilage degradation marker
of urinary CTX-II in CSMC021C2301 throughout the study period. In
CSMC021C2302 a comparable treatment effect was observed in the
ﬁrst year of study, but the treatment effect diminished in the sec-
ond year of the study. At the 24months study end point a treatment
effect was observed in CSMC021C2301 (urine CTX-I: P < 0.0001;
serum OC: P < 0.0001; urine CTX-II: P ¼ 0.0003), albeit no treat-
ment effect in study CSMC021C2302 (urine CTX-I: P ¼ 0.29; serum
OC: P ¼ 0.62; urine CTX-II: P ¼ 0.57). The treatment effect is
considered non-signiﬁcant due to the hierarchical testing
procedure.2 2302 All All
Placebo sCT Placebo
520 N ¼ 508 N ¼ 1105 N ¼ 1092
9 (38.3) 204 (40.2) 368 (33.3) 405 (37.1)
1 (61.7) 304 (59.8) 737 (66.7) 687 (62.9)
.4 (7.03) 64.3 (6.83) 64.5 (6.92) 64.3 (6.61)
2 (85.0) 429 (84.4) 974 (88.1) 961 (88.0)
2 (13.8) 72 (14.2) 125 (11.3) 123 (11.3)
6 (1.2) 7 (1.4) 6 (0.5) 8 (0.7)
.1 (5.37) 29.0 (5.06) 29.1 (5.1) 28.9 (4.76)
2 (1.04) 3.52 (1.01) 3.38 (0.98) 3.45 (1.00)
6 (78.1) 401 (78.9) 919 (83.2) 914 (83.7)
4 (21.9) 107 (21.1) 186 (16.8) 178 (16.3)
4 (69) 250 (71) 240 (73) 243 (74)
0 (383) 1134 (403) 1127 (378) 1135 (392)
1SD range)
2302 All All
Placebo sCT Placebo
N ¼ 81 N ¼ 646 N ¼ 658
.152e0.371) 0.257 (0.165e0.401) 0.222 (0.136e0.363) 0.221 (0.138e0.353)
3.8e29.1) 20.1 (14.6e27.8) 22.3 (15.8e31.4) 22.1 (15.8e31.0)
.94e2.74) 1.75 (1.04e2.97) 1.53 (0.85e2.77) 1.52 (0.86e2.69)
52e460) 284 (171e475) 239 (133e431) 230 (128e413)
Table III
CMSC021C2301 treatment emergent AEs
AEs sCT (n ¼ 585) Placebo (n ¼ 584) sCT (n ¼ 520) Placebo (n ¼ 508)
At least one AE 548 (94%) 520 (89%) 474 (91%) 459 (90%)
AEs occurring with a frequency of 5%
Any musculoskeletal and connective tissue disorder 231 (39%) 267 (46%) 215 (41%) 232 (46%)
Arthralgia 89 (15%) 93 (16%) 86 (17%) 111 (22%)
Back pain 62 (11%) 59 (10%) 52 (10%) 54 (11%)
OA 36 (6%) 52 (9%) 14 (3%) 25 (5%)
Pain in extremity 38 (6%) 30 (5%) 27 (5%) 23 (5%)
Musculoskeletal pain 21 (4%) 30 (5%) 26 (5%) 20 (4%)
Any infections and infestations 231 (39%) 249 (43%) 197 (38%) 215 (42%)
Nasopharyngitis 43 (7%) 55 (9%) 34 (7%) 39 (8%)
Inﬂuenza 36 (6%) 52 (9%) 46 (9%) 40 (8%)
Cystitis 35 (6%) 17 (3%) n.a. n.a.
Pneumonia 28 (5%) 24 (4%) 20 (4%) 23 (5%)
Any gastrointestinal disorders 268 (46%) 150 (26%) 208 (40%) 152 (30%)
Nausea 82 (14%) 18 (3%) 77 (15%) 15 (3%)
Dyspepsia 59 (10%) 26 (4%) 48 (9%) 21 (4%)
Diarrhea 56 (10%) 25 (4%) 45 (9%) 27 (3%)
Any vascular disorders 160 (27%) 92 (16%) 128 (25%) 77 (15%)
Hot ﬂush 104 (18%) 24 (4%) 88 (17%) 22 (3%)
Hypertension 46 (8%) 52 (9%) 31 (6%) 39 (8%)
Any nervous system disorders 96 (16%) 87 (15%) 101 (19%) 73 (14%)
Headache 35 (6%) 28 (5%) 29 (6%) 27 (5%)
Dizziness n.a. n.a. 32 (6%) 17 (3%)
Any injury, poisoning and procedural complications 87 (15%) 95 (16%) 69 (13 %) 84 (17%)
Procedural pain 29 (5%) 20 (3%) n.a. n.a.
Any metabolism and nutrition disorders 76 (13%) 64 (11%) 68 (13%) 66 (13%)
Hypercholesterolemia 30 (5%) 36 (6%) 24 (5%) 24 (5%)
Any general disorders and administration site conditions 60 (10%) 53 (9%) 66 (13%) 46 (9%)
Any investigations 53 (9%) 53 (9%) 35 (7%) 32 (6%)
Any skin and subcutaneous tissue disorders 69 (12%) 36 (6%) 66 (13%) 42 (8%)
Any respiratory, thoracic and mediastinal disorders 48 (8%) 49 (8%) 43 (8%) 36 (7%)
Any cardiac disorders 38 (6%) 30 (5%) 30 (6%) 28 (6%)
Any surgical and medical procedures 27 (5%) 30 (5%) 20 (4%) 26 (5%)
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Fig. 2. JSW change s) at 12 and 24 months (LS means ± 95% CIs MMRM ANCOVAmodel). Open circles: Placebo; Closed circles: 0.8 mg oral sCT. Number of subjects Pla/sCT: A) month
0: 584/585; month 12: 478/427; month 24: 454/394; B) month 0: 508/520; month 12: 407/377; month 24: 337/300; C) month 0: 1092/1105; month 12: 885/804; month 24: 791/
694; D) month 0: 580/578; month 12: 473/420; month 24: 444/382; E) month 0: 503/515; month 12: 403/372; month 24: 330/295; F) month 0: 1083/1093; month 12: 876/792;
month 24: 774/677.
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Fig. 3. Change in WOMAC total, pain, stiffness and function in target knee during the 24 month treatment period (LS means ± 95% CIs MMRM ANCOVA). Open circles: Placebo;
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491/474; month 6: 439/426; month 12: 406/376; month 18: 387/345; month 24: 338/301; I) screening: 1090/1105; month 1: 1054/1006; month 6: 954/883; month 12: 885/804;
month 24: 792/694.
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The levels of sCT in plasma were assessed 15 min after dosing at
the last visit at month 24. The levels are detailed in Fig. 5. These
levels were signiﬁcantly lower compared to previous studies with
the oral formulation in phase I and II studies.
Safety measures
The safety population consisted of all patients treated that
received at least one dose. There were markedly higher incidences
of gastrointestinal disorders and hot ﬂushes in the active treatmentarms of both studies, but most markedly in the CSMC021C2301
study (Table III). No other AEs weremarkedly different between the
two groups in either study.
Discussion
OA is leading cause of disability affecting the joint. The present
investigation focused on symptomatic knee OA without further
subtype identiﬁcation and segregatione well knowing that an
important discussion on sub phenotypes of OA is ongoing in the
ﬁeld29. This patient population may be representative to OA in
general.
Table IV
Group differences (sCT-Pla) in changes based on MMRM ANCOVA analysis incl 95% CIs
Variable CSMC021C2301 CSMC021C2302 Combined studies
JSW (mm)
Target knee month 12 0.005 [0.077e0.068] 0.046 [0.050e0.142] 0.018 [0.041e0.077]
Target knee month 24 0.002 [0.085e0.081] 0.064 [0.046e0.175] 0.028 [0.039e0.096]
Non-target knee month 12 0.030 [0.098e0.038] 0.071 [0.014e0.156] 0.016 [0.037e0.070]
Non-target month 24 0.036 [0.044e0.117] 0.043 [0.055e0.141] 0.040 [0.023e0.102]
WOMAC total target knee (mm)
Month 01 56.0 [98.0e14.1] 18.9 [25.9e63.7] 21.0 [51.8e9.7]
Month 06 39.2 [93.5e15.1] 20.6 [78.6e37.3] 30.8 [70.5e8.9]
Month 12 77.9 [137.2e18.5] 18.2 [42.6e79.0] 33.3 [75.9e9.3]
Month 24 95.1 [156.4e33.9] 4.0 [61.9e69.6] 47.0 [92.2e1.9]
WOMAC pain target knee (mm)
Month 01 10.2 [20.1e0.3] 2.2 [8.6e13.0] 4.3 [11.6e3.0]
Month 06 8.8 [20.7e3.1] 1.5 [14.6e11.5] 5.1 [13.9e3.6]
Month 12 18.3 [30.9e5.6] 6.0 [7.2e19.2] 6.8 [15.9e2.4]
Month 24 21.5 [34.7e8.2] 2.9 [11.1e17.0] 9.6 [19.3e0.1]
WOMAC stiffness target knee (mm)
Month 01 6.2 [10.6e1.8] 0.7 [3.9e5.3] 2.9 [6.1e0.3]
Month 06 4.8 [10.2e0.6] 0.6 [6.0e4.9] 2.8 [6.6e1.1]
Month 12 10.2 [15.8e4.6] 1.5 [7.4e4.4] 6.0 [10.1e2.0]
Month 24 12.4 [18.3e6.5] 1.0 [5.3e7.2] 6.0 [10.3e1.7]
WOMAC function target knee (mm)
Month 01 39.3 [70.1e8.5] 15.8 [16.8e48.4] 13.7 [36.2e8.8]
Month 06 26.6 [65.9e12.6] 19.6 [61.5e22.2] 23.8 [52.5e4.8]
Month 12 48.3 [91.4e5.1] 12.7 [31.4e56.8] 20.2 [51.1e10.7]
Month 24 60.0 [104.4e15.6] 1.1 [48.8e46.7] 31.0 [63.7e1.7]
Urine CTXI (%)
Month 06 21.8 [25.5e17.9] 24.9 [33.9e14.8] 22.3 [25.7e18.7]
Month 12 20.2 [24.6e15.6] 20.1 [29.0e10.0] 20.3 [24.2e16.1]
Month 18 18.9 [23.4e14.1] 16.8 [29.3 to2.2] 18.6 [22.9e14.0]
Month 24 15.0 [19.8e9.9] 7.5 [19.9e6.8] 13.9 [18.5e9.1]
Serum OC (%)
Month 06 12.1 [13.9e10.1] 9.0 [14.6e3.0] 11.6 [13.4e9.8]
Month 12 12.6 [14.8e10.3] 11.8 [17.6e5.6] 12.5 [14.5e10.4]
Month 24 10.6 [13.2e8.0] 2.2 [10.4e6.8] 9.4 [11.9e6.8]
Urine CTXII (%)
Month 06 10.3 [14.6e5.6] 7.7 [17.4e3.2] 9.8 [13.8e5.6]
Month 12 9.3 [14.0e4.4] 12.7 [22.4e1.6] 9.8 [14.1e5.4]
Month 18 9.1 [14.2e3.6] 2.4 [15.8e13.3] 8.0 [12.9e2.9]
Month 24 10.2 [15.2e4.8] 3.6 [15.13e9.7] 8.9 [13.7e4.1]
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fying drugs, has been undertaken and completed, the anti-
resorptive bisphosphonate risedronate30,31 and strontium rane-
late32, the ﬁrst with a negative outcome, and the other with partial
positive data. Other approaches have been investigated, and failed
in phase II clinical settings either due to lack of efﬁcacy or AEs, such
as cathepsin K inhibitors, some MMP inhibitions33, INOS34 and
doxycycline35,36. This highlights the notion that OA is a complicated
disease, which affects multiple compartments in the joints, and
targeting only one parameter may not provide the requested relief,
neither for neither symptoms nor structure.
The present combined phase III clinical studies showed (1) No
signiﬁcant effect on JSN. (2) A potential effect on total WOMAC and
WOMAC subscores was observed in one study although not claimed
signiﬁcant as the primary endpoint of JSN failed to show signiﬁ-
cance. (3) A potential small effect on markers of bone and cartilage
degradation, CTX-I and CTX-II respectively, and no positive balance
between bone formation and bone resorption.
JSN discussion
In neither of the present studies, a signiﬁcant inhibition of JSN
was achieved. The decrease in JSW in the placebo group at the 2-
year endpoint was in alignment with the expected decrease of
0.34 mm used in the sample size calculations but the expected
treatment effect of a 40% reduction corresponding to a treatment
effect of 0.14 mm was not achieved. In CSMC021C2301 thetreatment effect was 0.00 mm [95% CI: 0.09e0.08 mm], and in
CSMC021C2302 the treatment effect was 0.06 mm [95% CI:
0.05e0.18 mm].
Pain and function
At present there is a considerable debate in the literature on the
effect of sCT on pain, albeit no long term RCT have investigated
these effects carefully37. In the CSMC021C2301 study we observed
an effect on pain, stiffness and function, but as a hierarchical testing
procedure was applied for the co-primary endpoints no beneﬁcial
treatment effect can be claimed as the ﬁrst endpoint of JSN failed to
show signiﬁcance. The treatment effect was not reproduced in the
CSMC021C2302 study. Generally, a minimum reduction of 10% of
the maximum possible total WOMAC score is accepted as clinically
signiﬁcant38. The reduction observed in CSMC021C2301 in total
WOMAC-score of 95 mm out of a total of 2400 mm, equals a
reduction of 4%, which therefore does not qualify for clinical sig-
niﬁcance. In the context of drug tolerability vs level of pain
reduction, it should be noted that signiﬁcantly more patients dis-
continued the trial prematurely due to AEs in the group receiving
active treatment compared to placebo. Emerging pain studies
highlight that pain perception, and in particular OA referred pain,
needs to be carefully investigated to understand the context of the
pain medication and possible effects39e42, suggesting that further
patient segregation may be needed for understanding and optimal
efﬁcacy of sCT on OA pain and pain subtypes.
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Fig. 4. Levels relative to baseline of urinary CTX-I, serum osteocalcin, and urinary CTX-II (LS means ± 95% CIs MMRM ANCOVA). Open circles: Placebo; Closed circles: 0.8 mg oral sCT.
Number of subjects Pla/sCT: A) and G) month 0: 571/574; month 6: 490/438; month 12: 464/416; month 18: 441/383; month 24: 436/387; B) and H) month 0: 80/69; month 6: 79/
68; month 12: 80/69; month 18: 76/67; month 24: 79/69; C) and I) month 0: 651/643; month 6: 569/506; month 12: 544/485; month 18: 517/450; month 24: 515/456; D) month 0:
577/578; month 6: 509/454; month 12: 474/424; month 24: 446/389; E) all time points 81/68; F) month 0: 658/646; month 6: 590/522; month 12: 555/492; month 24: 527/457.
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With regards to bone resorption, surprisingly, and in contrast to
the 40% reduction in bone resorption seen in other studies16e18,22,43,
we found only a 20% reduction in study CSMC021C2301 (the study
with the signiﬁcant effect on pain and function), and a transient
effect in study CSMC021C2302. The biomarker population was
considerably larger in CSMC021C2301 where all subjects were
includedwhereas biomarkers weremeasured in a subpopulation of
149 subjects only in CSMC021C2302, which results in an imbalance.
There was a 10% reduction in the bone formation marker of osteo-
calcin in the active group compared to placebo in CSMC021C2301.
This is as expected for an anti-resorptive treatment, consequent to
the coupling between bone resorption and bone formation. This has
been observed for most traditional anti-resorptive treatments such
as SERMS, estrogens, bisphosphonates, cathepsin K inhibitors and
anti-RANKL44,45. There was 10% reduction in the cartilage degra-
dation marker of urinary CTX-II in study CSMC021C2301, and a
transient effect in study CSMC021C2302. This should be compared
to the 25% decrease in CTX-II observed in previous studies of oral
sCT16e18,27 of 24-h urine. Note the different between 24-h urine and
spot measurement with up-to 65% decrease for CTX-I and 50% for
CTX-II, in response to oral Calcitonin16,18,23e27. The 10% decrease incartilage degradation may be insufﬁcient to reach the threshold for
detection by JSN. This discrepancy in biomarkers may result from
the approximately four fold low exposure in the current study as
seen in Fig. 5, as compared to previous studies18,23e27, as there is a
direct linier relationship between exposure and effect on CTX-I27.
This may suggest that the current phase III failure is a combination
of a hypothesis and technical oral formulation failure. Importantly,
the present exposure levels of sCT were measured at the end point
after 2 years, compared to earlier time points for the comparison
studies. There may be compensatory mechanism hindering intes-
tinal uptake for long term for sCT, albeit the phase II data did not
suggest this trend43. Interestingly other anti-resorptives have
shown a decrease in CTX-I (bone resorption) with no effect on
cartilage degradation (CTX-II), suggestion that only selected in-
terventions may have dual action potential46. The effect size of CTX-
II needed to obtain a signiﬁcant change in JSN or cartilage volume
assessed by MRI, and a clinical signiﬁcant beneﬁt, remains to be
identiﬁed. Many studies have demonstrated that high levels of CTX-
II is associated with JSN47,48 and consequent hold prognostic value.
While CTX-II has been suggested to be the best described and
validated marker in the rheumatology ﬁeld, the efﬁcacy side of this
marker needs a successful phase III study in OA to be validated, as
with all other markers in the OA ﬁeld49.
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Fig. 5. Geometric mean (þstandard error) of plasma sCT 15 min post-dose in patients
given 0.8 mg oral sCT with 50 mL of water in the morning after an overnight fasting
period. For comparison studies in OA patients comparing day of treatment (modiﬁed
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The safety proﬁle was acceptable in both studies. Adverse re-
actions to calcitonin treatment were mainly gastrointestinal symp-
toms such as diarrhea, nausea andvomiting. Thesemild tomoderate
severe AEs disappear spontaneously when treatment is stopped.
Recently FDAcautioned against the use of sCT in osteoporosis, due to
apossible less favorable efﬁcacy/safety ratio compared toother bone
treatments. http://www.fda.gov/downloads/AdvisoryCommittees/
CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugs
AdvisoryCommittee/UCM343748.pdf). There was no causality
documented in calcitonin treatment, albeit cautionwas encouraged
in assessing the risk-beneﬁt ratio for various indications.
Conclusion
In conclusion, the present pivotal phase III clinical studies
demonstratednoreproducible clinical effects onpain, and functionof
oral sCT. This in contrast to preclinical50 and clinical observations
(phase 1 and 2)10,11,13e15,51. There is a direct linier relationship with
exposure of calcitonin and effect on the biomarker CTX-I27, suggest-
ing the lower levels of exposure tobeoneof thekeyparameters of the
lack of efﬁcacy,whichneed to beunderstood in largerdetails. Further
studies and investigations are needed to understand the lack of effect
on JSN, and the origin of this, and potentially to develop other mol-
ecules with higher potencies and more robust formulations.
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